**INFORMED CONSENT**

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Was the patient asked to consent to data submission?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of informed consent: _ _ _ / _ _ / _ _ (YYYY/MM/DD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is your centre using the EBMT consent form?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did the patient consent to data sharing with health authorities and/or researchers?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did the patient consent to data sharing with Health Technology Assessment bodies (HTA)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did the patient consent to data sharing with Market Authorisation Holders (MAH)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did the patient consent to their medical records being reviewed?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CENTRE IDENTIFICATION**

EBMT Centre Identification Code (CIC): __________

Hospital: ______________________________

Unit: ______________________________

Type of unit or team responsible for this cellular therapy:
(Optional; this is a coded replication of the above unit field and can be used by centres that have more than one department/unit reporting to the EBMT)

- [ ] Adults
- [ ] Allograft
- [ ] Autograft
- [ ] BMT unit
- [ ] Dept. Medicine
- [ ] Haematology
- [ ] Oncology
- [ ] Paediatrics
- [ ] Paediatric haematology
- [ ] Paediatric oncology

Contact person: _________________
EBMT Unique Identification Code (UIC): ________________________
(Patient number in EBMT database; complete if patient had a previous treatment and is already registered in the database)

Date of this report: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Hospital Unique Patient Number or code (UPN): ________________________
(Compulsory; registrations will not be accepted without this item. All treatments (transplants and CAR T-cell) performed in the same patient must be registered with the same patient identification number or code as this belongs to the patient and not to the treatment.)

Other type of patient identification code(s): ________________________
(Optional; to be used by the centre to register a patient code for internal use as necessary)

Date of birth: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Sex (at birth):
☐ Male
☐ Female

Initials: _________ / _________ (first name(s) / family name(s))

ABO group:
☐ A
☐ B
☐ AB
☐ O

Rh factor:
☐ Absent
☐ Present
☐ Not evaluated

If the patient had a previous cellular therapy or a stem cell transplant, please make sure that this previous treatment is registered and that the latest follow-up has been recorded using the appropriate follow-up form before proceeding; this is so relapse data and other events between transplants/advanced cellular therapies can be captured.
### INDICATION FOR CELLULAR THERAPY

- **Treatment of a primary disease:**
  - Indicate below for which disease this cellular therapy has been received.

  - **Primary Acute Leukaemia**
    - Acute Myelogenous Leukaemia (AML) (page 8)
    - Precursor Lymphoid Neoplasms (previously ALL) (page 12)
    - Other Primary Acute Leukaemia (page 15)

  - **Chronic Leukaemia**
    - Chronic Myeloid Leukaemia (CML) (page 16)
    - Chronic Lymphocytic Leukaemia (CLL) (page 16)
    - Prolymphocytic Leukaemias (PLL) and Other Chronic Leukaemias (page 17)

  - **Lymphoma**
    - Non-Hodgkin Lymphoma (NHL) (page 19)
    - Hodgkin’s Lymphoma (HL) (page 23)
    - Immunodeficiency-associated lymphoproliferative disorders (including PTLD) (page 23)

  - **Myelodysplastic Syndromes (MDS) and/or Myeloproliferative Neoplasm (MPN)**
    - MDS (page 24)
    - MDS/MPN (page 26)
    - MPN (page 28)

  - **Plasma Cell Disorders (PCD including Multiple Myeloma (MM))** (page 31)

  - **Bone Marrow Failure Syndromes including Aplastic Anaemia** (page 33)

  - **Haemoglobinopathy**

  - **Solid Tumour**

  - **Inherited Disorders**
    - Primary immune deficiencies (PID) (page 37)
    - Metabolic disorders (page 38)
    - Platelet and other inherited disorder (page 39)

  - **Histiocytic disorders**

  - **Autoimmune disease**
    - Connective tissue (page 41)
    - Vasculitis (page 41)
    - Arthritis (page 41)
    - Neurological (page 42)
    - Haematological (page 42)
    - Bowel disorder (page 42)
    - Other autoimmune disease (Diabetes, etc.) (page 42)

  - **Infections** (page 43)

  - **Other primary disease; specify:**

*Complete and attach the relevant disease classification sheet as per page numbers indicated above.*

**Date of diagnosis:** _ _ _ _ / _ _ / _ _ (YYYY/MM/DD)
INDICATION FOR CELLULAR THERAPY continued

☐ Treatment or prevention of complications
(derived from a previous treatment including HSCT or expected from a subsequent treatment)

Before continuing please make sure that the above mentioned transplant/ cellular therapy has been registered and that a MED-A annual follow-up form has been submitted; this is so relapse data and other events between transplants and/or cellular therapies can be captured.

☐ Both, treatment of primary disease and complication

Complete and attach the relevant disease classification sheet as per page numbers indicated above.

BASIC INFORMATION ON THE PLANNED CELLULAR THERAPY

Clinical setting:
(select only one)

☐ As per marketing approval / Standard of care / Institutional guidelines
☐ Hospital exemption
☐ Compassionate use / Accelerated access

☐ Investigational drug product (IDP)/ Clinical trial (CT)

<table>
<thead>
<tr>
<th>Phase</th>
<th>1</th>
<th>1/2</th>
<th>2</th>
<th>2/3</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blind trial</td>
<td>No</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomised trial</td>
<td>No</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Eudract number: ________________
USA NCT number: ________________
UMIN CT number: ________________

☐ Unknown

Cell origin:

☐ Autologous  --> Continue with 'Planned Cellular Therapy Product' on page 5

☐ Allogeneic

This product is manufactured from:

☐ A known donor never used to treat this patient (e.g. from a donor registry or related)
  --> Complete 'Donor' section on page 5

☐ A donor that is already registered as part of a previous treatment
  --> Skip 'Donor' section and continue with 'Planned Cellular Therapy Product' on page 5

☐ An unknown donor with no data available (e.g. from a commercial product)
  --> Skip 'Donor' section and continue with 'Planned Cellular Therapy Product' on page 5
DONOR INFORMATION

Date of birth: ___/___/___ (YYYY/MM/DD) OR Age at time of donation: _____ (years) _____ (months)
(only if date of birth not provided)

Sex (at birth):
☐ Male
☐ Female

Donor Identification:
Donor ID given by the treating centre (mandatory): __________________________
Global registration identifier for donors: __________________________
Donor ID given by the Donor Registry or Cord Blood Bank: __________________________
ION code of the Donor Registry or Cord Blood Bank (mandatory): __________________________
EuroCord code for the Cord Blood Bank (if applicable): __________________________
Name of Donor Registry or Cord Blood Bank: __________________________

PLANNED CELLULAR THERAPY PRODUCT
Description

If more than one planned cellular therapy product please replicate this section for each one of them.

Is the planned cellular therapy product a commercial product?
☐ No
☐ Yes

Will the planned cellular therapy product consist of more than one cell infusion unit?
☐ No
☐ Yes: Number of different cell infusion units: ____________
PLANNED CELLULAR THERAPY INFUSION PRODUCT
Description continued

If more than one planned cellular therapy product please replicate this section for each one of them.

Identification:

Name of manufacturer:
- Autolus
- Bluebird Bio
- Celgene/ Bristol Myer Squibb
- Celyad
- GlaxoSmithKline (GSK)
- Janssen (Johnson & Johnson)
- Kite Gilead
- Miltenyi
- Novartis
- Orchard
- Vertex
- Local hospital or university
- Other; specify: ___________________

Name of product (if applicable):
- Abecma
- Brenzaya
- Citlaca
- Eli-Cell
- Kymanex
- Tecartus
- Yescarta
- Other; specify: ___________________

Tissue source:
- Bone Marrow
- Peripheral Blood
- Umbilical Cord Blood
- Tumour
- Other; specify: ___________________

Collection procedure:
Date of collection: __/__/____ (YYYY/MM/DD)
(If more than one collection enter the date of the first collection.)
Number of collections: __________

END OF GENERAL PRE-INFUSION REGISTRATION

To complete PRE-INFUSION REGISTRATION please fill in the applicable disease classification.
## ACUTE LEUKAEMIAS

### Acute Myeloid Leukaemias (AML) - main disease code 1

### DISEASE

#### Classification:
- AML with recurrent genetic abnormalities
  - AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
  - AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11
  - Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML/RARA
  - AML with t(9;11) (p22;q23); MLLT3-MLL
  - AML with t(6;9) (p23;q24); DEK-NUP214
  - AML with inv(3) (q21;q26.2) or t(3;3) (q21;q26.2); RPN1-EVI1
  - AML (megakaryoblastic) with t(1;22) (p13;q13); RBM15-MKL1
  - AML with myelodysplasia related changes (previously "Acute Leukaemia transformed from MDS or MDS/MPN"):
    - No (continue with 'Predisposing Condition' below)
    - Yes (fill in the MDS (page 24) or MDS/MPN (page 26); then continue with 'Predisposing Condition' below)
  - AML with 11q23 (MLL) abnormalities
  - AML with BCR-ABL1
  - AML with mutated NPM1
  - AML with biallelic mutation of CEBPA
  - AML with mutated RUNX1

#### AML not otherwise categorised (NOS)
- AML with minimal differentiation (FAB M0)
- AML without maturation (FAB M1)
- AML with maturation (FAB M2)
- Acute myelomonocytic leukaemia (FAB M4)
- Acute monoblastic and monocytic leukaemia (FAB M5)
- Acute erythroid leukaemia (FAB M6)
- AML (megakaryoblastic) with t(1;22) (p13;q13); RBM15-MKL1
- Acute megakaryoblastic leukaemia (FAB M7)
- Acute basophilic leukaemia
- Acute pancytopenia with myelofibrosis

- Myeloid sarcoma
- Myeloid proliferations related to Down Syndrome
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Therapy related myeloid neoplasia (previously "Secondary Acute Leukaemia"; related to prior treatment but NOT after a previous diagnosis of MDS or MDS/MPN )
Did the patient have a predisposing condition prior to the diagnosis of leukaemia?
- No
- Yes:
  - Aplastic Anaemia
  - Bloom Syndrome
  - Fanconi Anaemia
  - Unknown

Is this a donor cell leukaemia?
(Only applicable if the patient has received an allograft prior to the diagnosis of acute leukaemia.)
- No
- Yes
- Not evaluated

### CHROMOSOME ANALYSIS

**Chromosome analysis at diagnosis (all methods including FISH):**
(Include all analyses before treatment; describe results of the most recent complete analysis)

- Normal

<table>
<thead>
<tr>
<th>Abnormal: Complex karyotype: (3 or more abnormalities)</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monosomal karyotype: (≥2 autosomal monosomes or 1 autosomal monosomy + at least 1 structural abnormality)</td>
<td>No</td>
</tr>
<tr>
<td>Monosomal karyotype: (≥2 autosomal monosomes or 1 autosomal monosomy + at least 1 structural abnormality)</td>
<td>Yes</td>
</tr>
<tr>
<td>Monosomal karyotype: (≥2 autosomal monosomes or 1 autosomal monosomy + at least 1 structural abnormality)</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

- Not done or failed
- Unknown
ACUTE LEUKAEMIAS
Acute Myeloid Leukaemias (AML) - main disease code 1

CHROMOSOME ANALYSIS continued

Transcribe the complete karyotype: ________________________________

OR

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>Abnormality Type</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(15;17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(8;21)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>inv(16)/t(16;16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11q23 abnormality type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(9;11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(11;19)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(10;11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(6;11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other abn(11q23); specify: _________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3q26 (EVI1) abnormality type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>inv(3)/t(3:3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(2;3)(p21;q26)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other (3q26)/EVI1 rearrangement; specify: _________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(6;9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abn 5 type (fill in only if an abn 5 is present):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>del (5q)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>monosomy 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Add(5q)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other abn(5q); specify: _________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abn 7 type (fill in only if an abn 7 is present):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>del(7q)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>monosomy 7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>add(7q)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other abn(7q); specify: _________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abn(17p)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(1;22)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trisomy 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other; specify: _________</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**MOLECULAR MARKER ANALYSIS**

Molecular Marker analysis at diagnosis:
- [ ] Absent
- [ ] Present
- [ ] Not done or failed
- [ ] Unknown

Indicate below whether the markers were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Description</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML1-ETO (RUNX1/RUNXT1)</td>
<td>Molecular product of t(8;21)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBF-MYH11</td>
<td>Molecular product of inv(16)(p13.1;q22) or (16;16)(p13.1;q22)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PML-RARα</td>
<td>Molecular product of t(15;17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLL-rearrangement/mutation (fill in only if 11q23 abnormality is present):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLLT3(AF9)-MLL</td>
<td>Molecular product of t(9;11)(p22;q23)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLL-PTD</td>
<td>Partial tandem duplication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLLT4(AF6)-MLL</td>
<td>Molecular product of t(6;11)(q27;q23)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ELL-MLL</td>
<td>Molecular product of t(11;19)(q23;p13.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLLT1(ENL)-MLL</td>
<td>Molecular product of t(11;19)(q23;p13.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLLT10(AF10)-MLL</td>
<td>Molecular product of t(10;11)(p12;q23)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other MLL-rearrangement; specify:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEK-NUP214(CAN)</td>
<td>Molecular product of translocation t(6;9)(p23;q34)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPN1-EVI1</td>
<td>Molecular product of inv(3)(q21q26.2) or t(3;3)(q21q26.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RBM15-MKL1</td>
<td>Molecular product of translocation t(1;22)(p13;q13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPM1 mutation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEBPA mutation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLT3-ITD (internal tandem duplication)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNMT3A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASXL1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP53</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RUNX1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c-KIT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other; specify:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ACUTE LEUKAEMIAS
Acute Myeloid Leukaemias (AML) - *main disease code 1*

**INVolvement AT DIAGNOSIS**

<table>
<thead>
<tr>
<th>Involvement at diagnosis:</th>
<th>No</th>
<th>Yes</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone Marrow:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testes/Ovary:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

Yes; specify: __________
**ACUTE LEUKAEMIAS**
**Precursor Lymphoid Neoplasms (previously ALL) - main disease code 1**

### DISEASE

**Classification:**

- [ ] B lymphoblastic leukaemia/lymphoma *(previously Precursor B-cell ALL)*
  - [ ] with t(9;22)(q34;q11.2); BCR-ABL1
  - [ ] with t(v;11q23); MLL rearranged
  - [ ] with t(1;19)(q23;p13.3); E2A-PBX1
  - [ ] with t(12;21)(p13;q22); TEL-AML1 (ETV-RUNX1)
  - [ ] with hyperdiploidy
  - [ ] with hypodiploidy
  - [ ] with t(5,14)(q31;q32); IL3-IGH
  - [ ] Not otherwise specified (NOS)
  - [ ] Other; specify: ____________

- [ ] T Lymphoblastic Leukaemia/Lymphoma *(previously Precursor T-cell ALL)*

**Secondary origin: Is this PLN related to prior exposure of therapeutic drugs or radiation?**

- [ ] No
- [ ] Yes
- [ ] Unknown

**Is this a donor cell leukaemia?**

*(Only applicable if the patient has received an allograft prior to the diagnosis of acute leukaemia.)*

- [ ] No
- [ ] Yes
- [ ] Not evaluated

### CHROMOSOME ANALYSIS

**Chromosome analysis at diagnosis (all methods including FISH):**

*(Include all analyses before treatment; describe results of the most recent complete analysis)*

- [ ] Normal

- [ ] Abnormal:
  - [ ] Complex karyotype: *(3 or more abnormalities)*
    - [ ] No
    - [ ] Yes
    - [ ] Unknown

- [ ] Not done or failed
- [ ] Unknown
**ACUTE LEUKAEMIAS**

**Precursor Lymphoid Neoplasms (previously ALL) - main disease code 1**

**CHROMOSOME ANALYSIS continued**

Transcribe the complete karyotype: ____________________________

OR

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>11q23 abnormalities <em>(fill in only if 11q23 abnormalities is present)</em></th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(9;22)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(4;11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other abn(11q23); specify: __________________________________________</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>t(12;21)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Hyperdiploidy (>46 chromosomes) *(fill in only if hyperdiploidy is present)*:**

<table>
<thead>
<tr>
<th>50 – 66 chromosomes</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisomy; specify extra chromosome: _____________________________</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Other hyperdiploid karyotype; number of chromosomes: ______</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
</tbody>
</table>

**Hypodiploidy (<46 chromosomes): *(fill in only if hypodiploidy is present)*:**

<table>
<thead>
<tr>
<th>Low hypodiploid; 32 - 39 chromosomes;</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Near haploid, 24-31 chromosomes;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monosomy; specify: _________________</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Other; number of chromosomes: ______</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>t(5;14)(q31;q32)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(1;19)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Molecular Marker Analysis**

Molecular Marker analysis at diagnosis:

- □ Absent
- □ Present
- □ Not done or failed
- □ Unknown
**MOLECULAR MARKER ANALYSIS continued**

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th><strong>Gene</strong></th>
<th><strong>Molecular Abnormality</strong></th>
<th><strong>Status</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BCR-ABL</strong></td>
<td>Molecular product of t(9;22)(q34;q11.2)</td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td><strong>MLL-rearrangement/mutation</strong> (fill in only if a MLL-rearrangement abnormality is present):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AFF1(AF4)-MLL</td>
<td>Molecular product of t(4;11)(q21;q23)</td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td>MLLT1(ENL)-MLL</td>
<td>Molecular product of t(11;19)(q23;p13.3)</td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td>MLLT3(AF9)-MLL</td>
<td>Molecular product of t(9;11)(p22;q23)</td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td>Other MLL-rearrangement; specify:</td>
<td></td>
<td>□ Absent □ Present</td>
</tr>
<tr>
<td><strong>TEL(ETV6)-AML1(RUNX1)</strong></td>
<td>Molecular product of t(12;21)(p13;q22)</td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td><strong>IL3-IGH</strong></td>
<td>Molecular product of t(5;14)(q31;q32)</td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td><strong>TCF3-PBX1</strong></td>
<td>Molecular product of translocation (1;19)(q23;p13.3)</td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td><strong>IKZF1 (IKAROS)</strong></td>
<td></td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td><strong>NOTCH1 &amp; FBWX7</strong></td>
<td></td>
<td>□ Absent □ Present □ Not evaluated</td>
</tr>
<tr>
<td>Other; specify:</td>
<td></td>
<td>□ Absent □ Present</td>
</tr>
</tbody>
</table>

**White blood cell count at diagnosis:** ____________ $10^9$ cells/L  □ Not available/Unknown
ACUTE LEUKAEMIAS
Other Acute Leukaemias - main disease code 1

DISEASE

Classification:
Acute leukaemia of ambiguous lineage

- [ ] Acute undifferentiated leukaemia
- [ ] Mixed phenotype NOS
  - [ ] Mixed phenotype B/myeloid, NOS
  - [ ] Mixed phenotype T/myeloid, NOS
- [ ] Natural killer (NK) - cell lymphoblastic leukaemia/lymphoma
- [ ] Other: specify: __________

Secondary origin: Is this other acute leukaemia related to prior exposure of therapeutic drugs or radiation?

- [ ] No
- [ ] Yes
- [ ] Unknown

Is this a donor cell leukaemia?
(Only applicable if the patient has received an allograft prior to the diagnosis of acute leukaemia.)

- [ ] No
- [ ] Yes
- [ ] Not evaluated
CHRONIC LEUKAEMIAS
Chronic Myelogenous Leukaemias (CML) - main disease code 2

DISEASE

Classification:
(At least one investigation must be positive; note: CMML is not a CML but MDS/MPN.)

<table>
<thead>
<tr>
<th>t(9;22) (Chromosome analysis)</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>bcr-abl (Molecular marker analysis)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
</tbody>
</table>

CHRONIC LEUKAEMIAS
Chronic Lymphocytic Leukaemias (CLL) - main disease code 2

DISEASE

Classification:

- □ Chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma
- □ Richter’s syndrome:
  - Transformed from a previous known CLL? □ Yes: Date of original CLL diagnosis: _ _ _ _ / _ _ _ _ (YYYY/MM/DD)
  - □ No: Primary Richter (without previously known diagnosis of CLL)

CHROMOSOME ANALYSIS

Chromosome analysis at diagnosis (all methods including FISH):
(Include all analyses before treatment; describe results of the most recent complete analysis)

□ Normal
□ Abnormal
□ Not done or failed
□ Unknown

Transcribe the complete karyotype: __________________________

OR

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>Trisomy 12</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>del(13q14)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(11q22-23)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(17p)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
</tbody>
</table>

Other; specify: __________________________ □ Absent □ Present
MOLECULAR MARKER ANALYSIS

Molecular Marker analysis at diagnosis:

- Absent
- Present
- Not done of failed
- Unknown

Indicate below whether the markers were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>TP53 mutations</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other; specify:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CHRONIC LEUKAEMIAS
Prolymphocytic Leukaemias (PLL) and Others - main disease code 2

DISEASE

Classification:

- Prolymphocytic Leukaemia (PLL)
  - PLL; B-cell
  - PLL; T-cell
- Hairy Cell Leukaemia
- Other chronic leukaemia; specify: ______________________

CHROMOSOME ANALYSIS
only applicable for PLL

Chromosome analysis at diagnosis (all methods including FISH):
(Include all analyses before treatment; describe results of the most recent complete analysis)

- Normal
- Abnormal
- Not done or failed
- Unknown
CHRONIC LEUKAEMIAS
Prolymphocytic Leukaemias (PLL) and Others - main disease code 2

CHROMOSOME ANALYSIS continued
only applicable for PLL

Transcribe the complete karyotype: _____________________________________________

OR

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>inv(14)/t(14;14)(q11;q32)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>del(14)(q12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(11;14)(q23;q11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(7;14)(q35;q32.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(X;14)(q35;q11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>idic(8)(p11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other; specify:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IMMUNOPHENOTYPING
only applicable for T-cell PLL

Immunophenotype of T-cells at diagnosis:
*Note: Terminal deoxynucleotidyl transferase (TdT) must be negative.*

Indicate below whether the phenotypes were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD8+</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Lymphocyte count at diagnosis: _____________ 10^6 cells/L
# Lymphomas

**B-Cell Non-Hodgkin Lymphomas (NHL) - main disease code 3**

## Disease

**Classification:** Mature B-cell Neoplasms
- [ ] Splenic marginal zone lymphoma
- [ ] Extramedullary marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)
- [ ] Nodal marginal zone lymphoma
- [ ] Lymphoplasmacytic lymphoma (LPL)
- [ ] Waldenström macroglobulinemia (LPL with monoclonal IgM)

**International Prognostic Scoring System for Waldenström’s Macroglobulinemia (ISSWM):**
- [ ] Low risk (0-1 score points except age > 65)
- [ ] Intermediate risk (2 score points or age > 65 alone)
- [ ] High risk (3-5 score points)
- [ ] Not evaluated

**Follicular lymphoma**

**Grading:**
- [ ] Grade I
- [ ] Grade II
- [ ] Grade III
- [ ] Not evaluated

**Prognostic score (FLIPI):**
- [ ] Low risk
- [ ] Intermediate risk
- [ ] High risk
- [ ] Not evaluated

**Primary cutaneous follicle centre lymphoma**

**Mantle cell lymphoma**

**Diffuse large B-cell lymphoma (DLBCL), (NOS)**
- [ ] T-cell/histiocyte rich large B cell lymphoma
- [ ] Primary DLBCL of the CNS
- [ ] Primary cutaneous DLBCL, leg type
- [ ] EBV positive DLBCL of the elderly
- [ ] Germinal centre B-cell type (GCB) DLBCL
- [ ] Activated B-cell type (ABC or non-GCB) DLBCL
- [ ] DLBCL associated with chronic inflammation
- [ ] Lymphomatoid granulomatosis
- [ ] Primary mediastinal (thymic) large B-cell lymphoma
- [ ] Intravascular large B-cell lymphoma
- [ ] ALK-positive large B-cell lymphoma
- [ ] Plasmablastic lymphoma
- [ ] HHV8-positive DLBCL,NOS
- [ ] Primary effusion lymphoma (PEL)
- [ ] Burkitt lymphoma (BL)
- [ ] High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
- [ ] B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (Intermediate DLCL/BL)
- [ ] B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (Gray zone lymphoma)
- [ ] Other B-cell lymphoma; specify: ________________

**International prognostic score (IPI):**
- [ ] Low risk (0-1 score points)
- [ ] Low-intermediate risk (2 score points)
- [ ] High-intermediate risk (3 score points)
- [ ] High risk (4-5 score points)
- [ ] Not evaluated

**KI-67 (proliferation index):** __% positive  

[ ] Not evaluated
**LYMPHOMAS**

**B-Cell Non-Hodgkin Lymphomas (NHL) - main disease code 3**

**DISEASE continued**

Transformed from another type of lymphoma at the event leading to this cellular therapy?

- [ ] No
- [ ] Yes: Date of original diagnosis: ______/____/____ (YYYY/MM/DD)
  
  Indicate the type of the original lymphoma: ______________________
  
- [ ] Unknown

Please complete Chromosome Analysis, Molecular Marker Analysis and Immunophenotyping sections only for patients receiving cellular therapy for the following types of B-cell NHL:

- Mantle cell lymphoma
- Waldenstrom macroglobulinaemia
- Burkitt lymphoma or Intermediate DLBCL/ Burkitt lymphoma

**CHROMOSOME ANALYSIS**

**Chromosome analysis at diagnosis (all methods including FISH):**

*Include all analyses before treatment; describe results of the most recent complete analysis*

- [ ] Normal
- [ ] Abnormal
- [ ] Not done or failed
- [ ] Unknown

If abnormal, complete this table according to the type of lymphoma diagnosed.

<table>
<thead>
<tr>
<th>Mantle cell lymphoma or Waldenstrom macro- globulinaemia</th>
<th>del(17p)</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>FISH used: No</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(2;8)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
<td></td>
</tr>
<tr>
<td>t(8;14)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
<td></td>
</tr>
<tr>
<td>t(8;22)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
<td></td>
</tr>
<tr>
<td>t(14;18)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
<td></td>
</tr>
<tr>
<td>myc rearrangement</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
<td></td>
</tr>
<tr>
<td>BCL2 rearrangement</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
<td></td>
</tr>
<tr>
<td>BCL6 rearrangement</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
<td></td>
</tr>
</tbody>
</table>
LYMPHOMAS
B-Cell Non-Hodgkin Lymphomas (NHL) - main disease code 3

Please complete Chromosome Analysis, Molecular Marker Analysis and Immunophenotyping sections only for patients receiving cellular therapy for the following types of B-cell NHL:

- Mantle cell lymphoma
- Waldenstrom macroglobulinaemia
- Burkitt lymphoma or Intermediate DLBCL/ Burkitt lymphoma

MOLECULAR MARKER ANALYSIS

Molecular Marker analysis at diagnosis:

☐ Absent
☐ Present
☐ Not done of failed
☐ Unknown

If abnormal, complete this table according to the type of lymphoma diagnosed.

<table>
<thead>
<tr>
<th></th>
<th>TP53 mutation</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mantle cell lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burkitt lymphoma or Intermediate DLBCL/ Burkitt lymphoma</td>
<td>myc rearrangement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate DLBCL/ Burkitt lymphoma</td>
<td>BCL2 rearrangement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BCL6 rearrangement</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IMMUNOPHENOTYPING

Immunophenotyping at diagnosis:

☐ Absent
☐ Present
☐ Not done of failed
☐ Unknown

If abnormal, complete this table according to the type of lymphoma diagnosed.

<table>
<thead>
<tr>
<th></th>
<th>SOX 11</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mantle cell lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burkitt lymphoma or Intermediate DLBCL/ Burkitt lymphoma</td>
<td>MYC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate DLBCL/ Burkitt lymphoma</td>
<td>BCL2/IgH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BCL6</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Lymphomas

**T-Cell Non-Hodgkin Lymphomas (NHL) - main disease code 3**

## Disease

**Classification:** Mature T-cell & NK-cell Neoplasms

- T-cell large granular lymphocytic leukaemia
- Aggressive NK-cell leukaemia
- Systemic EBV positive T-cell lymphoproliferative disease of childhood
- Hydroa vacciniforme-like lymphoma
- Adult T-cell leukaemia/lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Enteropathy-associated T-cell lymphoma
- Monomorphic epitheliotropic intestinal T-cell lymphoma
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Mycosis fungoides (MF)
- Sézary syndrome
- Lymphomatoid papulosis
- Primary cutaneous anaplastic large cell lymphoma
- Primary cutaneous gamma-delta T-cell lymphoma
  - Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma
  - Primary cutaneous CD4 positive small/medium T-cell lymphoma
- Peripheral T-cell lymphoma NOS (PTCL)
- Angioimmunoblastic T-cell lymphoma
- Anaplastic large-cell lymphoma (ALCL), ALK-positive
- Anaplastic large-cell lymphoma (ALCL), ALK-negative
- Other T-cell: specify: ____________________

**ISCL/EORT staging:**

- IA
- IB
- IIA
- IIIB
- IVA1
- IVA2
- IVB
- Not evaluated

**International prognostic score (IPI):**

- Low risk (0-1 score points)
- Low-intermediate risk (2 score points)
- High-intermediate risk (3 score points)
- High risk (4-5 score points)
- Not evaluated
# Lymphomas

## Hodgkin Lymphomas - main disease code 3

### Classification:

- [ ] Nodular lymphocyte predominant
- [ ] Classical predominant; lymphocyte-rich
- [ ] Classical predominant; nodular sclerosis
- [ ] Classical predominant; mixed cellularity
- [ ] Classical predominant; lymphocyte-depleted
- [ ] Classical predominant; NOS
- [ ] Other; specify: ___________________________

## Lymphomas

### Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD) - main disease code 3

### Classification:

- [ ] Lymphoproliferative disease associated with primary immune disorder
- [ ] Lymphoma associated with HIV infection
- [ ] Post-transplant lymphoproliferative disorder (PTLD)
  - [ ] Non-destructive PTLD
    - [ ] Plasmacytic hyperplasia PTLD
    - [ ] Infectious mononucleosis PTLD
    - [ ] Florid follicular hyperplasia PTLD
  - [ ] Polymorphic PTLD
  - [ ] Monomorphic PTLD
    - [ ] B-cell type
    - [ ] T-/INK-cell type
  - [ ] Classical Hodgkin lymphoma PTLD
- [ ] Other iatrogenic immunodeficiency-associated lymphoproliferative disorder

### Did the disease result from a previous solid organ transplant?

- [ ] No
- [ ] Yes: Date of transplant: _ _ _ / _ _ / _ _ (YYYY/MM/DD)
  - [ ] Type of transplant: [ ] Renal
  - [ ] Cardiac
  - [ ] Pulmonary
  - [ ] Other; specify: ___________________________
  - [ ] Unknown
**MYELODYSPLASTIC SYNDROMES (MDS)**

*main disease code 6*

### DISEASE

**Classification:**

- [ ] Refractory anaemia without ring sideroblasts (RA)
- [ ] Refractory anaemia with ring sideroblasts (RARS)
- [ ] Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
- [ ] Refractory cytopenia with multi-lineage dysplasia (RCMD)
- [ ] Refractory cytopenia with multi-lineage dysplasia with ringed sideroblasts (RCMD-RS)
- [ ] Refractory anaemia with excess of blasts-1 (RAEB-1)
- [ ] Refractory anaemia with excess of blasts-2 (RAEB-2)
- [ ] Childhood myelodysplastic syndrome (Refractory cytopenia of childhood; RCC)
- [ ] Myelodysplastic syndrome, unclassifiable (MDS-U)

**Therapy-related MDS?**

*Secondary origin*

- [ ] No
- [ ] Yes, disease related to prior exposure to therapeutic drugs or radiation
- [ ] Unknown

**Is this a donor cell leukaemia?**

*Only applicable if the patient has received an allograft prior to the diagnosis of MDS.*

- [ ] No
- [ ] Yes
- [ ] Not evaluated

### CHROMOSOME ANALYSIS

**Chromosome analysis at diagnosis (all methods including FISH):**

*Include all analyses before treatment; describe results of the most recent complete analysis*

- [ ] Normal
- [ ] Abnormal: Complex karyotype: (3 or more abnormalities)
  - [ ] No
  - [ ] Yes
  - [ ] Unknown
- [ ] Not done or failed
- [ ] Unknown
MYELODYSPLASTIC SYNDROMES (MDS)  
main disease code 6

CHROMOSOME ANALYSIS continued

Transcribe the complete karyotype: ____________________________

OR

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>del(Y)</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>abn 5 type (fill in only if an abn 5 is present):</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(5q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Other abn(5q); specify:</td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>del(20q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>abn 7 type (Fill in only if an abn 7 is present):</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(7q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Other abn(7q); specify:</td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>abn 3 type (Fill in only if an abn 3 is present):</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>inv(3)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>t(3q;3q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(3q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Other abn(3q); specify:</td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>del(11q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Trisomy 8</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Trisomy 19</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>i(17q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Other; specify:</td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
</tbody>
</table>

MOLECULAR MARKER ANALYSIS

Molecular Marker analysis at diagnosis:

☐ Absent  
☐ Present  
☐ Not done or failed  
☐ Unknown  

If an AML with myelodysplasia-related changes is entered, return to Acute Leukaemias on page 8 to continue.
COMBINED MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM (MDS/MPN) - main disease code 6

DISEASE

Classification:
- [ ] Chronic myelomonocytic leukaemia (CMMoL, CMML)
- [ ] Juvenile myelomonocytic leukaemia (JCMoL, JMML, JCML, JCMMO)
- [ ] Atypical CML (t(9;22) negative and BCR-ABL1 negative)

Therapy-related MDS/MPD?
(Secondary origin)
- [ ] No
- [ ] Yes, disease related to prior exposure to therapeutic drugs or radiation
- [ ] Unknown

CHROMOSOME ANALYSIS

Chromosome analysis at diagnosis (all methods including FISH):
(Include all analyses before treatment; describe results of the most recent complete analysis)

- [ ] Normal
- [ ] Abnormal: Complex karyotype: 3 or more abnormalities
  - [ ] No
  - [ ] Yes
  - [ ] Unknown
- [ ] Not done or failed
- [ ] Unknown

Transcribe the complete karyotype: ____________________________

OR

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>abn 1 type; specify: _____________</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>abn 5 type; specify: _____________</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>abn 7 type; specify: _____________</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Trisomy 8</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Trisomy 9</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(20q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(13q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Other; specify: _____________</td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
</tbody>
</table>
COMBINED MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM (MDS/MPN) - main disease code 6

MOLECULAR MARKER ANALYSIS

Molecular Marker analysis at diagnosis:
- Absent
- Present
- Not done or failed
- Unknown

Indicate below whether the markers were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BCR-ABL</strong>; Molecular product of t(9;22)(q34;q11.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>JAK2 mutation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FIP1L1-PDGFR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PTPN-11</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>K-RAS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>N-RAS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CBL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other; specify: ____________</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MYELOPROLIFERATIVE NEOPLASM (MPN)

*main disease code 6*

**Classification:**

- [ ] Primary myelofibrosis (Chronic idiopathic myelofibrosis; fibrosis with myeloid metaplasia)
- [ ] Polycythaemia vera
- [ ] Essential or primary thrombocythaemia
- [ ] Hyper eosinophilic syndrome (HES)
- [ ] Chronic eosinophilic leukaemia (CEL)
- [ ] Chronic neutrophilic leukaemia
- [ ] Systemic mastocytosis
- [ ] Mast cell leukaemia
- [ ] Mast cell sarcoma
- [ ] MPN not otherwise specified
- [ ] Myeloid and lymphoid neoplasms with FGFR1 abnormalities (Stem cell leukaemia-lymphoma syndrome, 8p11 syndrome)
- [ ] Other; specify: __________________

**Therapy-related MDS/MPD?**

*(Secondary origin)*

- [ ] No
- [ ] Yes, disease related to prior exposure to therapeutic drugs or radiation
- [ ] Unknown

**IPPS risk score for myelofibrosis:**

- [ ] Low risk
- [ ] Intermediate-1
- [ ] Intermediate-2
- [ ] High risk
- [ ] Not evaluated
## MYELOPROLIFERATIVE NEOPLASM (MPN)

### Main disease code 6

### CHROMOSOME ANALYSIS

**Chromosome analysis at diagnosis** *(all methods including FISH):*
*(Include all analyses before treatment; describe results of the most recent complete analysis)*

<table>
<thead>
<tr>
<th>Normal</th>
<th>Abnormal: Complex karyotype:</th>
<th>No</th>
<th>Yes</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>(3 or more abnormalities)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Not done or failed
- Unknown

Transcribe the complete karyotype: ____________________________

OR

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>abn 1 type; specify: ____________</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>abn 5 type; specify: ____________</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>abn 7 type; specify: ____________</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Trisomy 8</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Trisomy 9</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(20q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>del(13q)</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Other; specify: ____________</td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
</tbody>
</table>

### MOLECULAR MARKER ANALYSIS

**Molecular Marker analysis at diagnosis:**

- Absent
- Present
- Not done or failed
- Unknown
## MOLECULAR MARKER ANALYSIS continued

Indicate below whether the markers were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCR-ABL; Molecular product of t(9;22)(q34;q11.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JAK2 mutation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If present: allele burden ____%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cMPL mutation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calreticulin (CALR) mutation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIP1L1-PDGFR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other; specify: ____________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PLASMA CELL DISORDERS (PCD) incl. MULTIPLE MYELOMA (MM)

main disease code 4

DISEASE

Classification:

- Multiple myeloma (MM)
  - MM; heavy chain and light chain
  - MM; light chain
  - MM; non-secretory
  - Check light and/or heavy chain types as applicable
- Heavy chain type:
  - IgG
  - IgA
  - IgD
  - IgE
  - IgM (not Waldenstrom)
- Light chain type:
  - Kappa
  - Lambda
- Plasma cell leukaemia
- Solitary plasmacytoma of bone
- Primary amyloidosis
- POEMS
- Monoclonal light and heavy chain deposition disease (LCDD/HCDD)
- Other; specify: ________________

Staging at diagnosis:

Salmon & Durie staging for multiple myeloma:
(Please tick both columns.)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>II</td>
<td>B</td>
</tr>
</tbody>
</table>

Revised ISS:

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>ISS1 without high risk FISH and normal LDH</td>
</tr>
<tr>
<td>II</td>
<td>not R-ISS I or III</td>
</tr>
<tr>
<td>III</td>
<td>any ISS with high risk FISH and/or high LDH</td>
</tr>
</tbody>
</table>

ISS STAGE:

<table>
<thead>
<tr>
<th>Stage</th>
<th>β2-µglob (mg/L)</th>
<th>Albumin (g/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>&lt; 3.5</td>
<td>&gt; 35</td>
</tr>
<tr>
<td>II</td>
<td>OR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt; 3.5</td>
<td>&lt; 35</td>
</tr>
<tr>
<td></td>
<td>3.5 ≤ 5.5</td>
<td>any</td>
</tr>
<tr>
<td>III</td>
<td>&gt; 5.5</td>
<td>any</td>
</tr>
</tbody>
</table>
# PLASMA CELL DISORDERS (PCD) incl. MULTIPLE MYELOMA (MM)

**main disease code 4**

## CHROMOSOME ANALYSIS

*Not applicable for Primary amyloidosis.*

**Chromosome analysis at diagnosis (all methods including FISH):**

*(Include all analyses before treatment; describe results of the most recent complete analysis)*

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>Abnormal: Complex karyotype:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(3 or more abnormalities)</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>No done or failed</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Transcribe the complete karyotype: __________________________________________

**OR**

Indicate below whether the abnormalities were absent, present or not evaluated.

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>del(13q14)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(11;14)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abn(17q)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>del(17p)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(4;14)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(14;16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1q amplification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myc rearrangement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other; specify:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## MOLECULAR MARKER ANALYSIS

*Not applicable for Primary amyloidosis.*

**Molecular Marker analysis at diagnosis:**

- Absent
- Present
- Not done or failed
- Unknown
# BONE MARROW FAILURE SYNDROMES (BMF) incl. APLASTIC ANAEMIA (AA)

*main disease code 7*

## DISEASE

### Classification:

**Acquired:**

- [ ] Severe Aplastic Anaemia (SAA)
- [ ] Amegakaryocytosis, acquired (not congenital)
- [ ] Acquired Pure Red Cell Aplasia (PRCA) (not congenital)
- [ ] Paroxysmal nocturnal haemoglobinuria (PNH)
- [ ] Acquired Pure White Cell Aplasia
- [ ] Other acquired cytopenic syndrome; specify: __________________________

**Etiology:**

- [ ] Secondary to hepatitis
- [ ] Secondary to toxin/other drug
- [ ] Idiopathic
- [ ] Other; specify: __________________________

**Congenital:**

- [ ] Amegakaryocytosis / thrombocytopenia
- [ ] Fanconi anaemia
- [ ] Diamond-Blackfan anaemia (congenital PRCA)
- [ ] Shwachman-Diamond Syndrome
- [ ] Dyserythropoietic anaemia
- [ ] Dyskeratoris congenita
- [ ] Other congenital anaemia; specify: __________________________
### HAEMOGLOBINOPATHY

*main disease code 1*

**Classification:**

- [ ] Thalassaemia
  - [ ] Beta 0
  - [ ] Beta+
  - [ ] Beta E
  - [ ] Beta S (sickle cell + thalassaemia): Percentage sickle cell: _________ %
- [ ] Sickle Cell Disease
- [ ] Other haemoglobinopathy; specify: ____________________________
# SOLID TUMOURS

*main disease code 5*

## DISEASE

### Classification:

- □ Bone sarcoma (excluding Ewing sarcoma/PNET)
- □ Breast
- □ Central nervous system tumours (include CNS PNET)
- □ Colorectal
- □ Ewing sarcoma (ES)/PNET, extra-skeletal
- □ Ewing sarcoma(ES)/PNET, skeletal
- □ Germ cell tumour, extragonadal only
- □ Germ cell tumour, gonadal
- □ Head and neck
- □ Hepatobiliary
- □ Kidney cancer excluding Wilms’s tumour
- □ Lung cancer, non-small cell
- □ Lung cancer, small cell
- □ Medulloblastoma
- □ Melanoma
- □ Neuroblastoma
- □ Ovarian (carcinoma)
- □ Pancreatic
- □ Prostate
- □ Renal cell
- □ Retinoblastoma
- □ Rhabdomyosarcoma
- □ Soft tissue sarcoma (excluding Rhabdo. and extra-skeletal ES)
- □ Thymoma
- □ Wilms’s tumour
- □ Other; specify: __________________________

### TNM classification:

<table>
<thead>
<tr>
<th>Type:</th>
<th>Tumour:</th>
<th>Nodes:</th>
<th>Metastases:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td>TX</td>
<td>NX</td>
<td>MX</td>
</tr>
<tr>
<td></td>
<td>T0</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T1</td>
<td>N1</td>
<td>M1</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N2</td>
<td>Not evaluated</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N3</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>Not evaluated</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>Not evaluated</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Final Registry 55: Cellular Therapy Form — Pre-Infusion Registration_v1.0 page 35 of 45
SOLID TUMOURS
*main disease code 5*

DISEASE continued

**Disease-specific staging:**
- [ ] I
- [ ] II
- [ ] III
- [ ] IV
- [ ] Not evaluated
- [ ] Unknown

**Breast carcinoma risk factors and staging at diagnosis (Breast carcinoma only):**

**Receptor status:**

- Estrogen (ER):  
  - [ ] Negative
  - [ ] Positive: ER values: __________
  - [ ] Not evaluated

- Progesteron (PgR):  
  - [ ] Negative
  - [ ] Positive: PgR values: __________
  - [ ] Not evaluated

- HER2/neu (c-erb-B2):  
  - [ ] Negative
  - [ ] Positive
  - [ ] Not evaluated

**Defined by:**  
- [ ] ICH 3+
- [ ] IHC 1/2+ and FISH+

**Axillary lymph nodes at surgery:**  
- Nº positive / Nº examined = /  
- [ ] Not evaluated

**Sentinel Node:**  
- [ ] Negative
- [ ] Positive
- [ ] Not evaluated

**Carcinoma type (tick only one):**  
- [ ] Ductal carcinoma
- [ ] Lobular carcinoma

**Proliferation index (activity by Ki67 or MiB1 immunostaining): __________ % of positive cells**

**Germ cell tumour risk factors and staging at diagnosis (Germ cell tumours only):**

**Histological classification:**  
- [ ] Seminoma
- [ ] Non-seminoma

**Site of origin:**  
- [ ] Gonadal
- [ ] Extra-gonadal:  
  - [ ] retroperitoneal
  - [ ] mediastinal
  - [ ] Other sites; specify: __________
INHERITED DISORDERS
Primary Immune Deficiencies (PID) - main disease code 8

**Classification:**

- [ ] Absence of T and B cells SCID
- [ ] Absence of T, normal B cell SCID
- [ ] ADA deficiency (Adenosine deaminase deficiency)
- [ ] Ataxia telangiectasia
- [ ] Bare lymphocyte syndrome
- [ ] Cartilage hair hypoplasia
- [ ] CD 40 Ligand deficiency
- [ ] Chediak-Higashi syndrome
- [ ] Chronic granulomatous disease
- [ ] Common variable immunodeficiency
- [ ] DiGeorge anomaly
- [ ] Immune deficiencies, not otherwise specified
- [ ] Kostmann syndrome-congenital neutropenia
- [ ] Leukocyte adhesion deficiencies
- [ ] Neutrophil actin deficiency
- [ ] Omenn syndrome
- [ ] PNP deficiency (Purine nucleoside phosphorylase deficiency)
- [ ] Reticular dysgenesis
- [ ] SCID, other; specify: ____________________
- [ ] SCID, unspecified
- [ ] Wiskott Aldrich syndrome
- [ ] X-linked lymphoproliferative syndrome
- [ ] Other; specify: ____________________
## INHERITED DISORDERS

### Inherited Disorders of Metabolism - main disease code 8

<table>
<thead>
<tr>
<th>Classification</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenoleukodystrophy</td>
<td></td>
</tr>
<tr>
<td>Aspartyl glucosaminuria</td>
<td></td>
</tr>
<tr>
<td>B-glucuronidase deficiency (VII)</td>
<td></td>
</tr>
<tr>
<td>Fucosidosis</td>
<td></td>
</tr>
<tr>
<td>Gaucher disease</td>
<td></td>
</tr>
<tr>
<td>Glucose storage disease</td>
<td></td>
</tr>
<tr>
<td>Hunter syndrome (II)</td>
<td></td>
</tr>
<tr>
<td>Hurler syndrome (IH)</td>
<td></td>
</tr>
<tr>
<td>I-cell disease</td>
<td></td>
</tr>
<tr>
<td>Krabbe disease (globoid leukodystrophy)</td>
<td></td>
</tr>
<tr>
<td>Lesch-Nyhan (HGPRT deficiency)</td>
<td></td>
</tr>
<tr>
<td>Mannosidosis</td>
<td></td>
</tr>
<tr>
<td>Maroteaux-Lamy (VI)</td>
<td></td>
</tr>
<tr>
<td>Inherited disorders of metabolism, not otherwise specified</td>
<td></td>
</tr>
<tr>
<td>Metachromatic leukodystrophy</td>
<td></td>
</tr>
<tr>
<td>Morquio (IV)</td>
<td></td>
</tr>
<tr>
<td>Mucolipidoses, unspecified</td>
<td></td>
</tr>
<tr>
<td>Mucopolysaccharidosis (V)</td>
<td></td>
</tr>
<tr>
<td>Mucopolysaccharidosis, unspecified</td>
<td></td>
</tr>
<tr>
<td>Niemann-Pick disease (Type A,B)</td>
<td></td>
</tr>
<tr>
<td>Niemann-Pick disease (Type C,D,E)</td>
<td></td>
</tr>
<tr>
<td>Neuronal ceroid – lipofuscinosis (Batten disease)</td>
<td></td>
</tr>
<tr>
<td>Polysaccharide hydrolase abnormalities, unspecified</td>
<td></td>
</tr>
<tr>
<td>Sanfilippo (III)</td>
<td></td>
</tr>
<tr>
<td>Scheie syndrome (IS)</td>
<td></td>
</tr>
<tr>
<td>Wolman disease</td>
<td></td>
</tr>
<tr>
<td>Other; specify:</td>
<td></td>
</tr>
</tbody>
</table>
### INHERITED DISORDERS
Platelet and Other Inherited Disorders - *main disease code 8*

#### DISEASE

**Classification:**

- [ ] Glanzmann thrombasthenia
- [ ] Other inherited platelet abnormalities: specify: __________________________
- [ ] Osteopetrosis (malignant infantile osteopetrosis)
- [ ] Other osteoclast defects: specify: __________________________
HISTIOCYTIC DISORDERS

main disease code 9

DISEASE

Classification:

☐ Histiocytic disorders, not otherwise specified
☐ Familial erythro/haemophagocytic lymphohistiocytosis (FELH)
☐ Langerhans Cell Histiocytosis (Histiocytosis-X)
☐ Haemophagocytosis (reactive or viral associated)
☐ Histiocytic sarcoma (malignant histiocytosis)
☐ Other: specify: ________
AUTOIMMUNE DISORDERS

main disease code 10

DISEASE

Classification:

Connective tissue:

☐ Systemic sclerosis (SS)

Involvement/clinical problem:

☐ diffuse cutaneous
☐ limited cutaneous
☐ SSc sine scleroderma
☐ Mixed Connective Tissue Disease (MCTD)
☐ Other; specify: ______________

☐ Systemic lupus erythematosus (SLE)
☐ Polymyositis dermatomyositis
☐ Sjögren syndrome
☐ Antiphospholipid syndrome
☐ Other type of connective tissue disease; specify: ______________

Vasculitis:

☐ Wegener granulomatosis
☐ Classical polyarteritis nodosa
☐ Microscopic polyarteritis nodosa
☐ Churg-Strauss
☐ Giant cell arteritis
☐ Takayasu
☐ Behçet syndrome
☐ Overlap necrotising arteritis
☐ Other; specify: ______________

Arthritis:

☐ Rheumatoid arthritis
☐ Psoriatic arthritis/psoriasis
☐ Juvenile idiopathic arthritis (JIA), systemic (Still's disease)
☐ Juvenile idiopathic arthritis (JIA), articular

☐ oligoarticular onset
☐ polyarticular onset

☐ Other Juvenile idiopathic arthritis; specify: ______________
☐ Other arthritis; specify: ______________
**Classification:**

### Neurological diseases:
- [ ] Multiple Sclerosis
- [ ] Myasthenia gravis
- [ ] Amyotrophic lateral sclerosis (ALS)
- [ ] Chronic inflammatory demyelinating polyneuropathy (CIDP)
- [ ] Neuromyelitis Optica (NMO)
- [ ] Other autoimmune neurological disorder; specify: ______________________

### Haematological diseases:
- [ ] Idiopathic thrombocytopenic purpura (ITP)
- [ ] Haemolytic anaemia
- [ ] Evan syndrome
- [ ] Autoimmune lymphoproliferative syndrome (primary diagnosis, not subsequent to transplant)
- [ ] Other haematological autoimmune disease; specify: ______________________

### Bowel diseases:
- [ ] Crohn's disease
- [ ] Ulcerative colitis
- [ ] Other autoimmune bowel disease; specify: ______________________

### Other autoimmune diseases:
- [ ] Grave's disease
- [ ] Insulin-dependent diabetes (IDD)
- [ ] Other autoimmune disease; specify: ______________________
### OTHER PRIMARY DISEASES

**Infections - main disease code 14**

**Classification:**

- ☐ Prevention/Prophylaxis

**Treatment:**

- ☐ Adenovirus
- ☐ BK virus
- ☐ Cytomegalovirus (CMV)
- ☐ Epstein-Barr virus
- ☐ Human herpes virus
- ☐ Human immunodeficiency virus (HIV)
- ☐ Other virus; specify: __________
- ☐ Candida
- ☐ Aspergillus
- ☐ Other fungus; specify: __________
- ☐ Other infection; specify: __________

### OTHER PRIMARY DISEASES

**Neurological Disorders - main disease code 12**

**Classification:**

- ☐ Duchenne muscular dystrophy
- ☐ Acute cerebral vascular ischemia
- ☐ Amyotrophic lateral sclerosis (ALS)
- ☐ Parkinson's disease
- ☐ Spinal cord injury
- ☐ Cerebral palsy
- ☐ Congenital hydrocephalus
- ☐ Other; specify: __________
### OTHER PRIMARY DISEASES

**Cardiovascular (Heart) Diseases** - *main disease code 13*

**Classification:**

- [ ] Acute myocardial infarction (AMI)
- [ ] Chronic coronary artery disease (ischemic, cardiomyopathy)
- [ ] Heart failure (non-ischemic etiology)
- [ ] Other cardiovascular disease
- [ ] Limb ischemia
- [ ] Thromboangiitis obliterans
- [ ] Other peripheral vascular disease
- [ ] Other; specify: ____________________

### OTHER PRIMARY DISEASES

**Musculoskeletal Disorders** - *main disease code 15*

**Classification:**

- [ ] Avascular necrosis of femoral head
- [ ] Osteoarthritis
- [ ] Osteogenesis imperfecta
- [ ] Traumatic joint injury
- [ ] Other; specify: ____________________

---

**END OF PRE-INFUSION REGISTRATION & DISEASE CLASSIFICATION SHEETS**
### Change history:

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>v1.0</td>
<td>9-Feb-2022</td>
<td>First final version</td>
</tr>
</tbody>
</table>